Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Has announcements × Priapism × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Carcinoma, Non-Small-Cell Lung 14 Multiple Myeloma 8 Neoplasms 7 Parkinson Disease 4, Autosomal Dominant Lewy Body 6 Colorectal Neoplasms 6 Recurrence 5 Breast Neoplasms 5 Sarcoma 4 Ovarian Neoplasms 4 Neoplasm Metastasis 4 Melanoma 4 Lymphoma, Large B-Cell, Diffuse 4 Lymphoma, Follicular 4 Biliary Tract Neoplasms 4 Salivary Gland Neoplasms 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 Pheochromocytoma 3 Paraganglioma 3 Pancreatic Neoplasms 3 Neuroendocrine Tumors 3 Lymphoma, Mantle-Cell 3 Lymphoma, B-Cell, Marginal Zone 3 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3 Leukemia 3 Graft vs Host Disease 3 Glioma 3 Cholangiocarcinoma 3 Burkitt Lymphoma 3 Bronchiolitis Obliterans Syndrome 3 von Hippel-Lindau Disease 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01895361 2020-01-31

SUSTAIN

Reprixys Pharmaceutical Corporation

Phase 2 Completed

198 enrolled 18 charts 1 FDA

Classical hematology

Anemia, Sickle Cell, Priapism

Data powered by HemOnc (CC BY 4.0) Colophon ⚡